AARD•benzinga•
RBC Capital Initiates Coverage On Aardvark Therapeutics with Outperform Rating, Announces Price Target of $21
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga